William Blair Has Negative Outlook of Medtronic Q3 Earnings

Medtronic plc (NYSE:MDT - Free Report) - Analysts at William Blair lowered their Q3 2025 earnings estimates for Medtronic in a report released on Tuesday, November 19th. William Blair analyst M. Andrew now expects that the medical technology company will earn $1.36 per share for the quarter, down from their prior forecast of $1.37. The consensus estimate for Medtronic's current full-year earnings is $5.46 per share. William Blair also issued estimates for Medtronic's Q4 2025 earnings at $1.62 EPS, FY2025 earnings at $5.46 EPS and Q2 2026 earnings at $1.43 EPS.

A number of other research analysts have also commented on the stock. Oppenheimer upped their price objective on shares of Medtronic from $92.00 to $94.00 and gave the company a "market perform" rating in a research report on Wednesday, August 21st. UBS Group upgraded shares of Medtronic from a "sell" rating to a "neutral" rating and raised their price target for the stock from $76.00 to $90.00 in a research note on Thursday, August 15th. Piper Sandler raised their target price on Medtronic from $85.00 to $90.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 21st. Daiwa America upgraded Medtronic to a "strong-buy" rating in a research report on Friday, August 23rd. Finally, Stifel Nicolaus boosted their target price on shares of Medtronic from $85.00 to $87.00 and gave the company a "hold" rating in a research note on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $95.19.

Medtronic Trading Down 1.0 %

Shares of Medtronic stock opened at $84.11 on Thursday. The company has a market cap of $107.87 billion, a price-to-earnings ratio of 25.72, a PEG ratio of 2.42 and a beta of 0.84. Medtronic has a 1 year low of $75.96 and a 1 year high of $92.68. The company's fifty day simple moving average is $89.17 and its 200-day simple moving average is $84.84. The company has a current ratio of 1.84, a quick ratio of 1.61 and a debt-to-equity ratio of 0.51.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.01. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The firm had revenue of $8.40 billion during the quarter, compared to analyst estimates of $8.27 billion. During the same period in the previous year, the company earned $1.25 EPS. The company's revenue for the quarter was up 5.2% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Olstein Capital Management L.P. lifted its holdings in Medtronic by 19.2% during the third quarter. Olstein Capital Management L.P. now owns 87,000 shares of the medical technology company's stock worth $7,833,000 after acquiring an additional 14,000 shares in the last quarter. Manning & Napier Advisors LLC bought a new position in Medtronic in the second quarter valued at approximately $25,643,000. Ferguson Wellman Capital Management Inc. acquired a new position in shares of Medtronic in the third quarter valued at approximately $9,486,000. Harvest Portfolios Group Inc. boosted its stake in Medtronic by 6.5% in the 3rd quarter. Harvest Portfolios Group Inc. now owns 689,131 shares of the medical technology company's stock worth $62,042,000 after purchasing an additional 42,112 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Medtronic by 6.3% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 368,682 shares of the medical technology company's stock worth $29,019,000 after purchasing an additional 21,995 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.